Erschienen in:
01.02.2014 | Letter
Malignant hyperthermia in the intensive care setting
verfasst von:
Frank Schuster, Susanne Moegele, Stephan Johannsen, Norbert Roewer
Erschienen in:
Critical Care
|
Ausgabe 1/2014
Einloggen, um Zugang zu erhalten
Excerpt
Malignant hyperthermia (MH) is a life-threatening, inherited disorder of skeletal muscle calcium homeostasis. In susceptible individuals, exposure to trigger agents such as volatile anesthetics and depolarizing muscle relaxants, typically administered to induce or maintain general anesthesia, may lead to a hypermetabolic muscular syndrome [
1]. Recently, an anesthetic conserving device (AnaConDa
®; Sedana Medical AB, Geretsried, Germany) was introduced for sedation of intensive care patients using volatile anesthetics, associated with shorter wake-up and extubation time, reduced duration of mechanical ventilation and earlier hospital discharge [
2]. …